Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom.

Ellen BerniDaniel MurphyJames WhitehousePete ConwayPaola Di MaggioCraig J CurrieChris Poole

Published in: Current medical research and opinion (2018)

Rifaximin-α 550 mg twice daily in patients with recurrent episodes of OHE was estimated to generate cost savings and improved clinical outcomes compared to standard care over 5 years.

Keyphrases

irritable bowel syndrome
healthcare
palliative care
early onset
quality improvement
physical activity
cross sectional